“Global Anti-Obesity Drugs market set to grow to $6.3bn by 2023” says new Visiongain report

20 November 2018
Pharma

Visiongain has launched a new pharma report: Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

The Global Anti-Obesity Drugs Market is segmented into mechanism of action, duration of action, prescription vs. OTC and innovator vs. generic drugs. Mechanism of action (MoA) is further classified as Incretin mimetics/GLP-1 agonists, Lipase inhibitors, Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics and others. Most of the anti-obesity drugs have gone off-patent and thus this drug market is also marketed in to two markets as Innovator and Branded drugs. In addition, the market is marketed as prescription and over-the-counter (OTC) based on need for prescription for dispensing the drug.

The lead analyst of the report commented "During the forecast period, the global market is driven by the raising prevalence of overweight and obesity population; increasing awareness about the disease; growing diagnosis & treatment rates; obesity being recognized as a disease, adoption of national and international level policies by various countries.

In the global market, challenges continue with huge healthcare budget constraints, weak late-stage promising pipeline, generic competition, unavailability of safer & effective treatments, and availability of alternate therapies."

Leading companies featured in the report include Eisai/Arena, GlaxoSmithKline (GSK), Novo Nordisk, Orexigen/Takeda, Roche, Teva, Vivus

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Neurostimulation Devices market set to grow to $13bn by 2024” says new Visiongain report

Neurostimulation is an advanced treatment which helps to reduce certain types of chronic pain.

28 November 2018

Read

“Global Anti-Obesity Drugs market set to grow to $6.3bn by 2023” says new Visiongain report

Most of the anti-obesity drugs have gone off-patent and thus this drug market is also marketed in to two markets as Innovator and Branded drugs.

20 November 2018

Read

“Global Laboratory Information Systems market set to grow to $2.8bn by 2023” says new Visiongain report

The laboratory information system (“LIS”) industry includes set of programs and hardware, which are part of an integrated system designed for healthcare information.

19 November 2018

Read

“Global Biologics market set to grow to $250bn by 2023” says Visiongain

Bio therapeutics is the fastest-growing sector in the pharmaceutical industry, with total revenues reaching up to $163 billion.

14 November 2018

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1